The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis

Rosalie A. Scholtes MD | Daniël H. van Raalte MD | Ricardo Correa-Rotter MD | Robert D. Toto MD | Hiddo J. L. Heerspink PhD | Valerie Cain MS | C. David Sjöström MD | Peter Sartipy PhD | Bergur V. Stefánsson MD

Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centres, location VUmc, Amsterdam, The Netherlands
Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Bogier Clinical and IT Solutions Inc., Raleigh, North Carolina, United States
AstraZeneca, Gothenburg, Sweden
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden

Correspondence
Daniël H. van Raalte, Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centres, location VUmc, Amsterdam, The Netherlands, Email: d.vanraalte@vumc.nl

Funding information
European Association for the Study of Diabetes; AstraZeneca, Grant/Award Number: GPP3

Peer Review
The peer review history for this article is available at https://publons.com/publon/10.1111/dom.13923.

Abstract

Aims: Renin-angiotensin system inhibitors (RASI) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria and may complement RASI by offering additional renal protection. This post hoc analysis investigated the effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASI at baseline.

Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over 12–24 weeks across 13 placebo-controlled studies in patients with T2D with a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASI at baseline.

Results: Compared with patients with RASI at baseline (n = 957), patients without RASI (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid (sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASI treatment at baseline.

Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASI at baseline.

Keywords
cardiac and renal risk factors, dapagliflozin, RASI, SGLT-2 inhibitors, type 2 diabetes
1 | INTRODUCTION

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as dapagliflozin, lower blood glucose levels by blocking glucose reuptake in the proximal tubule, resulting in urinary glucose excretion.1 Beyond their glucose-lowering effect, evidence from recent cardiovascular (CV) outcomes trials (CVOTs)2-4 indicates that whereas the effects of SGLT-2 inhibitors on major adverse CV events might be limited to patients with established CV disease, the beneficial effects on heart failure and renal function might be applicable to a broad population of patients with type 2 diabetes (T2D).5-7 In particular, in these trials, SGLT-2 inhibitors delayed the progression of nephropathy.2,3,8 Given the large burden of both CV disease and diabetic kidney disease in patients with T2D—despite optimal treatment of CV and renal risk factors using a multifactorial intervention9—the SGLT-2 inhibitor-induced cardiac and renal effects are highly salutary.

However, currently, it is unclear how the use of background medication may potentially alter the effects of SGLT-2 inhibition on cardiac and renal risk factors, such as urinary albumin-to-creatinine ratio (UACR), blood pressure (BP) or serum uric acid (sUA), as they have only reported the effect of background medication on outcomes. Most important in this regard are the renin-angiotensin system inhibitors (RASI): angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers. These drugs are known to affect systemic haemodynamics, reverse cardiac remodelling after injury and modulate renal haemodynamics by dilating the renal efferent arteriole. It is important to ascertain whether the beneficial effects of dapagliflozin on cardiac and renal risk factors are modified by concomitant RAS inhibition and, equally important, whether RAS inhibition could alter the safety and tolerability of SGLT-2 inhibitors.

Therefore, in the current post hoc analysis of previously reported dapagliflozin studies, we investigated the effect of dapagliflozin on multiple important markers of cardiac and kidney function as well as on safety aspects in patients with T2D treated with or without RASi.

2 | MATERIALS AND METHODS

2.1 | Study design

This was a post hoc analysis of data pooled from 13 previously reported phase II and III, randomized, placebo- or active-controlled, 12- or 24-week studies conducted during 2005–2012 (Table S1; see Supporting Information).10-22 The studies included patients with T2D aged ≥18 years, with body mass index ≥40–45 kg/m² and glycated haemoglobin (HbA1c) ≥6.5%–12% (47.5–107.7 mmol/mol). The protocols of the original studies used for this post hoc analysis did not require RASI use as an entry criterion. In this analysis, patients with T2D with a UACR ≥30 mg/g at baseline were divided into two groups: patients who received RASI at baseline (with RASI treatment) and patients who did not receive RASI at baseline (without RASI treatment). Single spot urine samples were collected at each study visit. The pooled patient population was randomized to receive dapagliflozin 10 mg/day or placebo for up to 24 weeks.

2.2 | Outcome measures

Baseline demographics and disease characteristics were assessed. Changes in the following parameters were assessed from baseline over the 24-week treatment period with dapagliflozin versus placebo: UACR, estimated glomerular filtration rate (eGFR), HbA1c, haematocrit, body weight, sUA, systolic BP (SBP) and diastolic BP (DBP). We analysed the impact of change in UACR on the overall population adjusting for UACR, age, sex, race, body weight, SBP, eGFR and RASI treatment at baseline. The overall safety profile, including adverse events (AEs) and serious AEs (SAEs), was also assessed.

2.3 | Statistical analyses

Descriptive statistics were used for presenting baseline characteristics and safety data. For efficacy parameters, the mean change from baseline values and 95% confidence intervals (CIs) were derived using a longitudinal repeated-measures mixed model with fixed terms for study, treatment, week, subgroup, week-by-treatment interaction, treatment-by-subgroup interaction and treatment-by-week-by-subgroup interaction, as well as the fixed covariates of baseline, baseline-by-study and baseline-by-week interactions. In addition, for the percentage change in UACR, a longitudinal repeated-measures mixed model pooling subgroups was performed, with fixed terms for study, treatment, week and week-by-treatment interaction, as well as the fixed covariates of baseline, baseline-by-study and baseline-by-week interactions. In addition, for the percentage change in UACR, a longitudinal repeated-measures mixed model pooling subgroups was performed, with fixed terms for study, treatment, week and week-by-treatment interaction, as well as the fixed covariates of baseline, baseline-by-study and baseline-by-week interactions. For continuous data were tested using ANOVA with group and study in the model. All statistical analyses were performed using SAS® version 9.2 (SAS Institute Inc., Cary, North Carolina).

3 | RESULTS

3.1 | Disposition and baseline characteristics

Demographic and baseline characteristics are shown in Table 1. Of the 1259 patients analysed, at baseline most (n = 957) participants among these studies were prescribed RASI treatment as compared with the group without RASI treatment (n = 302). Patients without RASI treatment compared with those with RASI treatment at baseline were younger (by approximately 5 years), had a shorter duration of diabetes (approximately 7 vs. 12 years), had higher eGFR and had lower UACR, sUA, body weight and SBP at baseline (Table 1). In both
groups, most patients were white and there were more men than women.

3.2 Effect of dapagliflozin on urinary albumin-to-creatinine ratio, estimated glomerular filtration rate, glycated haemoglobin and haematocrit

The observed changes in the placebo-adjusted treatment effects of dapagliflozin at week 24 in UACR (Figure 1A), eGFR (Figure 1B) and HbA1c (Figure 1C) were of similar magnitudes in patients without RASi treatment compared with those with RASi treatment at baseline.

3.3 Effect of dapagliflozin on body weight, serum uric acid, and systolic and diastolic blood pressure

The placebo-adjusted mean reductions (95% CI at week 24) in body weight and sUA were more pronounced in patients without RASi treatment compared with those treated with RASi at baseline.
24; that is, $-2.60$ kg ($-3.31$, $-1.90$) versus $-1.76$ kg ($-2.19$, $-1.34$) ($P = 0.0569$ treatment by RASi subgroup interaction; Figure 1E) and $-0.61$ ($-0.83$, $-0.40$) mg/dL versus $-0.36$ ($-0.49$, $-0.23$) mg/dL ($P = 0.0433$ treatment by RASi subgroup interaction; Figure 1F), respectively. Although a decrease was observed in both groups, the placebo-adjusted mean reductions in SBP and DBP at week 24 were numerically greater in patients without RASi treatment compared with those with RASi treatment at baseline (Figure 1G and 1H). Similarly, placebo-adjusted mean reduction in SBP and DBP at week 24 was numerically greater in patients who were not on diuretics than in those...
3.4 | Effect of covariates on placebo-adjusted change in urinary albumin-to-creatinine ratio in all patients receiving dapagliflozin

The placebo-adjusted effect of dapagliflozin treatment on UACR was not affected by treatment with RASi at baseline and was largely independent of other covariates such as age, race, body weight, SBP and eGFR (Figure 2).

3.5 | Safety

Overall, AEs were more common in patients treated with RASi (who were also older and had a longer duration of T2D) compared with patients without RASi treatment. However, among patients with RASi treatment, the AE profile was similar in the placebo and dapagliflozin treatment groups (Table 2). Among the group without RASi treatment, the proportion of patients with at least one AE was greater in the dapagliflozin-treated patients than in the placebo-treated patients (Table 2).

4 | DISCUSSION

We show here, using a pooled analysis of 13 phase II and III studies in patients with T2D and increased albuminuria, that treatment with the SGLT-2 inhibitor dapagliflozin over 24 weeks provides similar clinically relevant improvements in CV and renal risk parameters, irrespective of treatment with RASi at baseline.

The cardio-renal protective effects of SGLT-2 inhibitors have been recently established by three large CVOTs.\textsuperscript{2-4} However, it is unclear whether the use of co-medication, specifically RASi, could modulate the beneficial effects on cardiac and renal outcomes and the safety profiles of SGLT-2 inhibitors. Thus, in this post hoc analysis we investigated the effect of dapagliflozin on multiple markers of cardio-renal function, as well as on safety aspects in patients with T2D treated with or without RASi before dapagliflozin initiation.

Regarding CV disease markers, an important observation was that regardless of RAS inhibition at baseline, haematocrit levels were increased, which could indicate either volume contraction\textsuperscript{23,24} or increase in erythropoiesis.\textsuperscript{25} Volume contraction corresponds to one of the main hypotheses for the CV benefits observed in the SGLT-2 inhibitor CVOTs: an increase in haematocrit, resulting in beneficial

### TABLE 2 Summary of adverse events

| Description                              | With RASi (N = 957) | Without RASi (N = 302) |
|------------------------------------------|---------------------|------------------------|
|                                         | PBO n = 481 | DAPA 10 mg n = 476     | PBO n = 146 | DAPA 10 mg n = 156 |
| At least one AE                          | 294 (61.1) | 313 (65.8)             | 75 (51.4)  | 100 (64.1)   |
| AEs leading to study drug discontinuation| 29 (6.0)    | 24 (5.0)               | 4 (2.7)    | 5 (3.2)      |
| At least one hypoglycaemic event          | 85 (17.7)  | 90 (18.9)              | 11 (7.5)   | 13 (8.3)     |
| At least one SAE                         | 51 (10.6)  | 41 (8.6)               | 2 (1.4)    | 6 (3.8)      |
| SAEs leading to study drug discontinuation| 10 (2.1)   | 0 (0.0)                | 1 (0.7)    | 1 (0.6)      |
| Deaths                                   | 4 (0.8)    | 3 (0.6)                | 0 (0.0)    | 1 (0.6)      |

Abbreviations: AE, adverse event; DAPA, dapagliflozin; PBO, placebo; RASI, renin-angiotensin system inhibitors; SAE, serious adverse event. Data are represented as n (%). Data shown include non-serious/serious AEs with onset on or after the first date of treatment and on or before the last day of treatment plus 4 days/30 days or up to and including the start date of the long-term period or up to the follow-up visit if earlier. Only hypoglycaemia reported as an SAE is included in the AE, related AE, SAE, related SAE and AE leading to discontinuation summaries.
cardiac haemodynamics.\textsuperscript{22} For example, Inzucchi et al showed in a mediation analysis of the EMPA-REG OUTCOME trial that the change in haematocrit from baseline mediated 51.8\% of the effect of empagliflozin versus placebo in the reduction of the risk of CV death.\textsuperscript{23} Conversely, although an increase in erythropoiesis could be a complementary mechanism for the increased levels of haematocrit, the extent to which this mechanism contributes to the CV benefits observed with empagliflozin is not clear.\textsuperscript{24}

As expected,\textsuperscript{3} a decrease in body weight was observed in patients treated with dapagliflozin. However, in combination with RASI the reduction in body weight was not as pronounced as without RASI. Previous studies have shown that the glucose-lowering efficacy of SGLT-2 inhibitors depends on renal function.\textsuperscript{26} In parallel, attenuation of weight loss would be expected with declining renal function. However, surprisingly, the reduction in body weight is found to be independent of eGFR\textsuperscript{27} and the underlying mechanism is still not understood. Given the post hoc nature of the analysis, any proffered mechanism for this weight loss pattern would probably be speculative.

In the present analysis, a decrease in sUA levels was observed in patients treated with or without RASI. To the extent that this may have CV benefit this is a salutary effect. Fractional excretion of UA has been shown to be related to urinary glucose excretion.\textsuperscript{28} Keeping in mind that in the present analysis the majority of the patients without RASI had normal kidney function, the glucose-mediated excretion of UA could possibly be larger compared with that in patients with RAS inhibition.

The most cited explanation for the renoprotective properties of SGLT-2 inhibitors is their ability to activate tubuloglomerular feedback\textsuperscript{29–32} thereby reducing intraglomerular pressure.\textsuperscript{33} Clinically, this is reflected in a decline in eGFR upon initiation of SGLT-2 inhibition and a rapid and sustained reduction in albuminuria,\textsuperscript{34} followed by stabilization and preservation of kidney function. The same was observed in the current analysis and has been demonstrated in other studies of other SGLT-2 inhibitors.\textsuperscript{2,4} The beneficial effects of SGLT-2 inhibition on renal outcomes, such as eGFR, have been shown in the EMPA-REG OUTCOME trial, CRESCENDO, CANVAS Program and DECLARE-TIMI 58 trial.\textsuperscript{2,4,7,36} However, none of these studies reported whether SGLT-2 inhibitors according to baseline RASI use modulated the effect on UACR.

Our analysis also showed that the magnitude of UACR reduction was similar in patients treated with and without RASI at baseline. This is in contrast to previous literature in which it has been proposed that SGLT-2 inhibition with concomitant RASI may synergistically boost the alternative RAS axis, leading to upregulation of angiotensin (1–7).

In our analysis, we did not find modulation by RASI or any indication of a possible synergistic effect, thus the effect of RASI is probably smaller. This would also explain why the magnitude of UACR reduction in our analysis was comparable in patients with and without RASI at baseline.

Interestingly, the placebo-adjusted treatment effect of dapagliflozin-induced UACR reduction was mostly independent of haemodynamic, metabolic, biochemical or physical factors. Nevertheless, these data suggest possible differences between sexes.\textsuperscript{38,39}

This largely independent UACR reduction is in line with previous findings with dapagliflozin, empagliflozin and canagliflozin.\textsuperscript{34,40,41} The albuminuria- and UACR-lowering effect of dapagliflozin is known to show large interindividual variations, and may only be partly explained by haemodynamic factors such as eGFR and SBP.\textsuperscript{40,42} Apparently, other effects of dapagliflozin, such as reduction in intraglomerular hypertension, account for the albuminuria-lowering properties, although we cannot eliminate confounding caused by measurement variability.

With respect to safety, concomitant use of RASI and dapagliflozin appears to show a safety profile similar to the known profile of dapagliflozin (i.e. no increase in drug discontinuation because of AEs or SAEs).

The present analysis has some limitations. First, patients with RASI had a longer duration of T2D and higher UACR and SBP, as well as lower eGFR, compared with those without RASI use at baseline. Thus, in general, patients with RASI had more severe chronic kidney disease and had more comorbid conditions at baseline. Further, this was a post hoc analysis of 13 randomized controlled studies, and the original studies were not designed to assess the interaction of dapagliflozin with concurrent RASI use. Hence, patients were not randomized according to treatment with or without RASI inhibition. Consequently, baseline characteristics differed between the dapagliflozin and placebo groups and this limited the analysis. Therefore, this analysis can only be interpreted as hypothesis generating. Another limitation was the heterogeneity across the pooled clinical studies, possibly caused by differences in study design, duration and baseline characteristics, which may cause variability in the treatment effects estimated across studies.

5 | CONCLUSIONS

In this post hoc analysis, the placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, HaB1c and haematocrit over 24 weeks were similar between patients with and without RAS inhibition at baseline. There were no additional safety findings for the dapagliflozin/RASI combination compared with RAS inhibition alone. Therefore, our data suggest that the use of RASI in combination with SGLT-2 inhibitors does not impact the biomarkers associated with CV and kidney function.

ACKNOWLEDGMENTS

The authors thank all the site investigators and patients who participated in the reported dapagliflozin studies. This study was funded by AstraZeneca. Editorial support and some medical writing support, which were in accordance with Good Publication Practice (GPP3) guidelines, were provided by Advait Joshi, PhD and Steven Tresker, both of Cactus Communications, and were funded by AstraZeneca. The sponsor was involved in the study design; collection, analysis and interpretation of data; report writing; and the decision to submit the manuscript for publication. This analysis was previously presented as an abstract and a poster at the European Association for the Study of Diabetes (EASD) 2018 meeting.
DATA STATEMENT
Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

CONFLICT OF INTEREST
R.A.S. has no conflicts of interest. D.V.R. has participated in advisory boards for AstraZeneca, Boehringer Ingelheim-Eli Lilly Alliance, MSD, Novo Nordisk and Sanofi, and has received research grants from AstraZeneca, Boehringer Ingelheim-Eli Lilly Alliance, MSD and Sanofi. All honoraria are paid to the employer Amsterdam University Medical Centres. R.C.-R. is an employee of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México; has participated in advisory boards for AbbVie (SONAR), AstraZeneca (DAPA-CKD) and Amgen (EVOLVE); is currently participating in clinical research studies for AstraZeneca, AbbVie and GSK; and has been a speaker in the past 2 years for AstraZeneca, AbbVie, Amgen, and Takeda. R.D.T. is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Quintiles, Quest Diagnostics, Relypsa and Reata Pharmaceuticals. H.J.L.H. is a consultant for Astellas, AbbVie, AstraZeneca, Boehringer Ingelheim, Fresenius, Gilead, Janssen, Mitsubishi Tanabe Pharma, Mundipharma and Merck; reports research grants from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim and Janssen; and has a policy that all honoraria are paid to University Medical Center, Groningen, The Netherlands. V.C. is a former employee of AstraZeneca and owns AstraZeneca stock. B.V.S., C.D.S., and P.S. are employees and shareholders of AstraZeneca.

AUTHOR CONTRIBUTIONS
R.A.S. and D.V.R. drafted the introduction and discussion. P.S., C.D.S., and B.V.S. designed the study. V.C. performed the statistical analyses. All authors participated in data interpretation and contributed to critical revisions of the manuscript.

ORCID
Rosalie A. Scholtes https://orcid.org/0000-0002-2794-2263
Daniël H. van Raalte https://orcid.org/0000-0003-2894-6124
Hiddo J. L. Heerspink https://orcid.org/0000-0002-3126-3730

REFERENCES
1. van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12:700-710.
2. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
3. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
4. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
5. Verma S, Juni P, Mazer CD. Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019;393:3-5.
6. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-39.
7. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306.
8. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
10. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-2233.
11. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159-169.
12. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218-1227.
13. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-2224.
14. Jabbour SA, Hardy E, Sugg J, Parikh SJ. Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740-750.
15. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252-1262.
16. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
17. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-1478.
18. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928-938.
19. Wilding J, Bailey C, Rigney U, Blak B, Beekman W, Emmas C. Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther. 2016;7:695-711.
20. Wilding JP, Norwood P, T’Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-1662.
21. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
22. Wilding JP, Woo V, Soler NG, et al. Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes.
23. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2012;35:156-405.

24. Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the SGLT2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:2667-2673.

25. Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40:771-776.

26. Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36:1260-1265.

27. Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93:231-244.

28. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. BioPharm Drug Dispos. 2014;35:391-404.

29. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep. 2018;18:27.

30. Heerspink HJ, Perkins BA, Fitchett DH, Hussain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;133:752-772.

31. Pecoits-Filho R, Perkovic V. Are SGLT2 inhibitors ready for prime time for CKD? Clin J Am Soc Nephrol. 2018;13:318-320.

32. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098-2107.

33. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:87-97.

34. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610-621.

35. Mayer GJ, Wanner C, Weir MR, et al. Analysis from the EMPA-REG OUTCOME(R) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96(2):489-504.

36. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606-617.

37. Kopecky C, Lytvyn Y, Domenig O, et al. Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. Diabetologia. 2019;62:1090-1093.

38. James GD, Sealey JE, Alderman M, et al. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens. 1988;1:124-131.

39. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13:1034-1039.

40. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597.

41. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691-704.

42. Heerspink HJL, Sjöström CD, Inzucchi SE, et al. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes Obes Metab. 2019;21:720-725.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Scholtes RA, van Raalte DH, Correa-Rotter R, et al. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Diabetes Obes Metab. 2020;22:549-556. https://doi.org/10.1111/dom.13923